Lanadelumab
Drugs Used In Hereditary Angioedema
Sold as TAKHZYRO
- Drug class
- Drugs Used In Hereditary Angioedema
- Availability
- Prescription only
- Routes
- Subcutaneous
- Markets covered
- 4
- Products on record
- 10
- FDA reports (12 mo)
- 417
Overview
Lanadelumab is an active pharmaceutical ingredient in the Drugs Used In Hereditary Angioedema group (B06AC). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 4 | April 17, 2026 |
| US United States | FDA | 1 | February 28, 2025 |
| EU European Union | EMA | 1 | October 2, 2025 |
| CA Canada | Health Canada | 4 | April 29, 2026 |
GBUnited Kingdom· MHRA
4 products
Uses
TAKHZYRO is indicated for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 2 years and older.
How to take
USUnited States· FDA
1 product
Uses
1 INDICATIONS AND USAGE TAKHZYRO ® is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 2 years and older. TAKHZYRO is a plasma kallikrein inhibitor (monoclonal antibody) indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 2 years and older.
( 1 )
How to take
EUEuropean Union· EMA
1 product
Uses
TAKHZYRO is indicated for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 2 years and older.
How to take
CACanada· Health Canada
4 products
4 products on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [4].
Brands in Canada (1)
Sources & citations
- [1]MHRA (UK) · PLGB549370020 · revised April 17, 2026
- [2]FDA DailyMed · 15f99d8c-efe7-4f… · revised February 28, 2025 [PDF]
- [3]European Medicines Agency · EMEA/H/C/004806 · revised October 2, 2025
- [4]Health Canada (DPD) · 02480948 · revised April 1, 2026
- [5]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.